
Joe M O'sullivan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10815045/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet, The, 2016, 387, 1163-1177.	6.3	1,570
2	Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncology, The, 2016, 17, 1047-1060.	5.1	941
3	Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet, The, 2018, 392, 2353-2366.	6.3	901
4	Radiation-induced bystander signalling in cancer therapy. Nature Reviews Cancer, 2009, 9, 351-360.	12.8	703
5	Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncology, The, 2014, 15, 738-746.	5.1	433
6	Cell-Specific Radiosensitization by Gold Nanoparticles at Megavoltage Radiation Energies. International Journal of Radiation Oncology Biology Physics, 2011, 79, 531-539.	0.4	388
7	Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncology, The, 2014, 15, 1397-1406.	5.1	351
8	Biological consequences of nanoscale energy deposition near irradiated heavy atom nanoparticles. Scientific Reports, 2011, 1, 18.	1.6	335
9	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. European Urology, 2020, 77, 508-547.	0.9	278
10	Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncology, The, 2016, 17, 1306-1316.	5.1	259
11	Nanodosimetric effects of gold nanoparticles in megavoltage radiation therapy. Radiotherapy and Oncology, 2011, 100, 412-416.	0.3	174
12	Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet, The, 2022, 399, 447-460.	6.3	173
13	A Randomized, Double-Blind, Dose-Finding, Multicenter, Phase 2 Study of Radium Chloride (Ra 223) in Patients with Bone Metastases and Castration-Resistant Prostate Cancer. European Urology, 2013, 63, 189-197.	0.9	154
14	Cell type-dependent uptake, localization, and cytotoxicity of 1.9 nm gold nanoparticles. International Journal of Nanomedicine, 2012, 7, 2673.	3.3	150
15	The effect of androgen deprivation therapy on body composition in men with prostate cancer: Systematic review and meta-analysis. Journal of Cancer Survivorship, 2010, 4, 128-139.	1.5	126
16	Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncology, The, 2015, 16, 1605-1616.	5.1	126
17	Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation. Carcinogenesis, 2008, 29, 1148-1156.	1.3	119
18	Chemotherapy-Induced CXC-Chemokine/CXC-Chemokine Receptor Signaling in Metastatic Prostate Cancer Cells Confers Resistance to Oxaliplatin through Potentiation of Nuclear Factor-ήB Transcription and Evasion of Apoptosis. Journal of Pharmacology and Experimental Therapeutics, 2008, 327, 746-759.	1.3	100

#	Article	IF	CITATIONS
19	Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. Lancet Oncology, The, 2012, 13, 549-558.	5.1	100
20	Consensus on molecular imaging and theranostics in prostate cancer. Lancet Oncology, The, 2018, 19, e696-e708.	5.1	90
21	Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial. European Urology, 2018, 73, 427-435.	0.9	84
22	Out-of-Field Cell Survival Following Exposure to Intensity-Modulated Radiation Fields. International Journal of Radiation Oncology Biology Physics, 2011, 79, 1516-1522.	0.4	83
23	Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial. Clinical Genitourinary Cancer, 2017, 15, 42-52.e8.	0.9	75
24	Gold nanoparticle cellular uptake, toxicity and radiosensitisation in hypoxic conditions. Radiotherapy and Oncology, 2014, 110, 342-347.	0.3	72
25	Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial. European Urology, 2016, 70, 875-883.	0.9	67
26	Bone-Targeting Radiopharmaceuticals Including Radium-223. Cancer Journal (Sudbury, Mass), 2013, 19, 71-78.	1.0	60
27	Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from aÂphaseÂIII randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases Journal of Clinical Oncology, 2012. 30. 8-8.	0.8	55
28	A Kinetic-Based Model of Radiation-Induced Intercellular Signalling. PLoS ONE, 2013, 8, e54526.	1.1	55
29	Adding Celecoxib With or Without Zoledronic Acid for Hormone-NaÃ⁻ve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial. Journal of Clinical Oncology, 2017, 35, 1530-1541.	0.8	54
30	Elevation of c-FLIP in Castrate-Resistant Prostate Cancer Antagonizes Therapeutic Response to Androgen Receptor–Targeted Therapy. Clinical Cancer Research, 2012, 18, 3822-3833.	3.2	53
31	A randomised controlled trial to evaluate the efficacy of a 6-month dietary and physical activity intervention for patients receiving androgen deprivation therapy for prostate cancer. Journal of Cancer Survivorship, 2015, 9, 431-440.	1.5	53
32	What is the Role of the Bystander Response in Radionuclide Therapies?. Frontiers in Oncology, 2013, 3, 215.	1.3	51
33	Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology, 2022, 82, 115-141.	0.9	51
34	Targeted Alpha Therapy: Current Clinical Applications. Cancer Biotherapy and Radiopharmaceuticals, 2020, 35, 404-417.	0.7	48
35	Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial. European Journal of Cancer, 2017, 71, 1-6.	1.3	45
36	DNA Damage Responses following Exposure to Modulated Radiation Fields. PLoS ONE, 2012, 7, e43326.	1.1	44

#	Article	IF	CITATIONS
37	Dose, dose-rate and field size effects on cell survival following exposure to non-uniform radiation fields. Physics in Medicine and Biology, 2012, 57, 3197-3206.	1.6	43
38	Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial. Journal of Clinical Oncology, 2022, 40, 825-836.	0.8	40
39	Assessing software upgrades, plan properties and patient geometry using intensity modulated radiation therapy (IMRT) complexity metrics. Medical Physics, 2011, 38, 2027-2034.	1.6	38
40	Recognizing Symptom Burden in Advanced Prostate Cancer: A Global Patient and Caregiver Survey. Clinical Genitourinary Cancer, 2018, 16, e411-e419.	0.9	36
41	Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program. BMC Cancer, 2019, 19, 12.	1.1	36
42	A Computational Model of Cellular Response to Modulated Radiation Fields. International Journal of Radiation Oncology Biology Physics, 2012, 84, 250-256.	0.4	35
43	The Efficacy and Safety of Conventional and Hypofractionated High-Dose Radiation Therapy for Prostate Cancer in an Elderly Population: A Subgroup Analysis of the CHHiP Trial. International Journal of Radiation Oncology Biology Physics, 2018, 100, 1179-1189.	0.4	33
44	Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer. Future Oncology, 2014, 10, 219-231.	1.1	30
45	A study of the biological effects of modulated 6 MV radiation fields. Physics in Medicine and Biology, 2010, 55, 1607-1618.	1.6	29
46	A phase I study of combined docetaxel and repeated high activity 186Re-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial). European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1990-1998.	3.3	29
47	The Role of Therapeutic Layering in Optimizing Treatment for Patients With Castration-resistant Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II). Urology, 2017, 104, 150-159.	0.5	29
48	Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5â€year followâ€up results from the STAMPEDE randomised trial (NCT00268476). International Journal of Cancer, 2022, 151, 422-434.	2.3	29
49	Disease Characteristics and Completion of Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Radium-223 in an International Early Access Program. Clinical Genitourinary Cancer, 2019, 17, 348-355.e5.	0.9	27
50	Advantages and limitations of navigation-based multicriteria optimization (MCO) for localized prostate cancer IMRT planning. Medical Dosimetry, 2014, 39, 205-211.	0.4	26
51	Short Androgen Suppression and Radiation Dose Escalation in Prostate Cancer: 12-Year Results of EORTC Trial 22991 in Patients With Localized Intermediate-Risk Disease. Journal of Clinical Oncology, 2021, 39, 3022-3033.	0.8	24
52	The Risk of Cardiovascular Disease in Prostate Cancer Patients Receiving Androgen Deprivation Therapies. Epidemiology, 2020, 31, 432-440.	1.2	22
53	The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer. European Urology, 2019, 75, e51-e52.	0.9	21
54	Implications of Intercellular Signaling for Radiation Therapy: A Theoretical Dose-Planning Study. International Journal of Radiation Oncology Biology Physics, 2013, 87, 1148-1154.	0.4	20

#	Article	IF	CITATIONS
55	Analysis of overall survival by number of radium-223 injections received in an international expanded access program (iEAP) Journal of Clinical Oncology, 2016, 34, 5082-5082.	0.8	20
56	Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness. European Urology Oncology, 2018, 1, 449-458.	2.6	19
57	Phase I/II trials of 186Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 620-629.	3.3	18
58	Radium-223 Within the Evolving Treatment Options for Metastatic Castration-resistant Prostate Cancer: Recommendations from a European Expert Working Group. European Urology Oncology, 2020, 3, 455-463.	2.6	17
59	Vasoactivity of Rucaparib, a PARP-1 Inhibitor, is a Complex Process that Involves Myosin Light Chain Kinase, P2 Receptors, and PARP Itself. PLoS ONE, 2015, 10, e0118187.	1.1	17
60	A randomised controlled trial to evaluate the efficacy of a 6 month dietary and physical activity intervention for prostate cancer patients receiving androgen deprivation therapy. Trials, 2010, 11, 86.	0.7	16
61	Failure to Achieve a PSA Level â‰໘ ng/mL After Neoadjuvant LHRHa Therapy Predicts for Lower Biochemical Control Rate and Overall Survival in Localized Prostate Cancer Treated With Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2007, 69, 1467-1471.	0.4	15
62	Relative biological effectiveness (RBE) and out-of-field cell survival responses to passive scattering and pencil beam scanning proton beam deliveries. Physics in Medicine and Biology, 2012, 57, 6671-6680.	1.6	15
63	Cellular signalling effects in high precision radiotherapy. Physics in Medicine and Biology, 2015, 60, 4551-4564.	1.6	15
64	A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1319-1327.	3.3	15
65	Non-inferiority randomised phase 3 trial comparing two radiation schedules (single vs. five fractions) in malignant spinal cord compression. British Journal of Cancer, 2020, 122, 1315-1323.	2.9	15
66	Use of radionuclides in metastatic prostate cancer. Current Opinion in Supportive and Palliative Care, 2012, 6, 310-315.	0.5	14
67	StereoTactic radiotherapy for wet Age-Related macular degeneration (STAR): study protocol for a randomised controlled clinical trial. Trials, 2016, 17, 560.	0.7	14
68	Impact of Hypofractionated Radiotherapy on Patient-reported Outcomes in Prostate Cancer: Results up to 5Âyr in the CHHiP trial (CRUK/06/016). European Urology Oncology, 2021, 4, 980-992.	2.6	14
69	Radium-223 Dichloride (Ra-223) for the Treatment of Metastatic Castration-resistant Prostate Cancer: Optimizing Clinical Practice in Nuclear Medicine Centers. The Journal of Oncopathology, 2015, 3, 1-25.	0.1	10
70	Time and Cell Type Dependency of Survival Responses in Co-cultured Tumor and Fibroblast Cells after Exposure to Modulated Radiation Fields. Radiation Research, 2015, 183, 656-664.	0.7	10
71	A novel CBCT-based method for derivation of CTV-PTV margins for prostate and pelvic lymph nodes treated with stereotactic ablative radiotherapy. Radiation Oncology, 2017, 12, 124.	1.2	9
72	Bone lesion absorbed dose profiles in patients with metastatic prostate cancer treated with molecular radiotherapy. British Journal of Radiology, 2018, 91, 20170795.	1.0	9

#	Article	IF	CITATIONS
73	Exercise for advanced prostate cancer: a multicomponent, feasibility, trial protocol for men with metastatic castrate-resistant prostate cancer (EXACT). Pilot and Feasibility Studies, 2019, 5, 102.	0.5	8
74	Mechanistic Modeling of Radium-223 Treatment of Bone Metastases. International Journal of Radiation Oncology Biology Physics, 2019, 103, 1221-1230.	0.4	8
75	Clinical and functional characterization of CXCR1/CXCR2 biology in the relapse and radiotherapy resistance of primary PTEN-deficient prostate carcinoma. NAR Cancer, 2020, 2, zcaa012.	1.6	8
76	Inverse planned constant dose rate volumetric modulated arc therapy (VMAT) as an efficient alternative to five-field intensity modulated radiation therapy (IMRT) for prostate. Journal of Radiotherapy in Practice, 2014, 13, 68-78.	0.2	7
77	Prostate cancer treated with brachytherapy; an exploratory study of dose-dependent biomarkers and quality of life. Radiation Oncology, 2017, 12, 53.	1.2	6
78	A radiobiological model of metastatic burden reduction for molecular radiotherapy: application to patients with bone metastases. Physics in Medicine and Biology, 2017, 62, 2859-2870.	1.6	6
79	Conventional in vivo irradiation procedures are insufficient to accurately determine tumor responses to non-uniform radiation fields. International Journal of Radiation Biology, 2015, 91, 257-261.	1.0	5
80	Toxicity and Efficacy of Concurrent Androgen Deprivation Therapy, Pelvic Radiotherapy, and Radium-223 in Patients with <i>De Novo</i> Metastatic Hormone-Sensitive Prostate Cancer. Clinical Cancer Research, 2021, 27, 4549-4556.	3.2	5
81	Dose estimation after a mixed field exposure: Radium-223 and intensity modulated radiotherapy. Nuclear Medicine and Biology, 2022, 106-107, 10-20.	0.3	5
82	Neoadjuvant Hormone Therapy for Radical Prostate Radiotherapy: Bicalutamide Monotherapy vs. Luteinizing Hormone–Releasing Hormone Agonist Monotherapy: A Single-Institution Matched-Pair Analysis. Clinical Genitourinary Cancer, 2012, 10, 190-195.	0.9	4
83	Investigating the influence of respiratory motion on the radiation induced bystander effect in modulated radiotherapy. Physics in Medicine and Biology, 2013, 58, 8311-8322.	1.6	4
84	Hormone therapy use and the risk of acute kidney injury in patients with prostate cancer: a population-based cohort study. Prostate Cancer and Prostatic Diseases, 2021, 24, 1055-1062.	2.0	4
85	Tumor Dosimetry on SPECT 186Re-HEDP Scans: Variations in the Results from the Reconstruction Methods Used. Cancer Biotherapy and Radiopharmaceuticals, 2007, 22, 121-124.	0.7	2
86	A novel tool for improving the interpretation of isotope bone scans in metastatic prostate cancer. British Journal of Radiology, 2020, 93, 20200775.	1.0	2
87	Where Do We See Alpha Emitters in Clinical Practice? A Radiation Oncology Perspective. Journal of Medical Imaging and Radiation Sciences, 2019, 50, S31-S33.	0.2	1
88	Reply to â€~Single high dose versus repeated bone-targeted radionuclide therapy'. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 515-517.	3.3	0
89	Use of bisphosphonates and other bone supportive agents in the management of prostate cancer—A UK perspective. International Journal of Clinical Practice, 2020, 74, e13611.	0.8	0